Loading...
•
Dec 31, 2021
Twist Bioscience Q1 2022 Earnings Report
Reported record revenues with SynBio particularly robust.
Key Takeaways
Twist Bioscience reported a strong start to the year with record orders and revenue. The company's biopharma team added new partners and programs, with the first Twist Biopharma-discovered antibody expected to enter clinical trials this year.
Record revenues of $42M, a 49% increase over fiscal 2021.
Orders increased 48% to $49.6M.
SynBio was particularly robust in the first quarter of fiscal 2022
First DNA data storage solution would be a Century Archive, storing data for 100 years
Twist Bioscience
Twist Bioscience
Forward Guidance
Twist provided updated financial guidance for the full fiscal year 2022.